Mucoadhesive Polymers in Peroral Peptide Drug Delivery. VI. Carbomer and Chitosan Improve the Intestinal Absorption of the Peptide Drug Buserelin In Vivo

AbstractPurpose. To evaluate the effect of the crosslinked poly(acrylate) carbomer 934P (C934P) and its freeze-dried neutralized sodium salt (FNaC934P) as well as chitosan hydrochloride on the intestinal absorption of the peptide drug buserelin. Methods. Buserelin was applied intraduodenally in control buffer, 0.5% (w/v) C934P, 0.5% (w/v) FNaC934P, 1.5% (w/v) chitosan hydrochloride or FNaC934P/chitosan hydrochloride (1:1 (v/v)) mixture in rats. Results. All polymer preparation showed a statistically significant improvement of buserelin absorption compared to the control solution. The absolute bioavailabilities for the different polymer preparations were: control, 0.1%; 0.5% FNaC934P, 0.6%; 0.5% C934P, 2.0%; chitosan hydrochloride, 5.1% and FNaC934P/chitosan hydrochloride (1:1 (v/v)) mixture, 1.0%. The higher bioavailability with chitosan hydrochloride compared to C934P and FNaC934P indicates that for buserelin the intestinal transmucosal transport enhancing effect of the polymer plays a more dominant role than the protection against proteases such as α-chymotrypsin. Conclusions. The mucoadhesive polymers carbomer 934P and chitosan hydrochloride are able to enhance the intestinal absorption of buserelin in vivo in rats, and may therefore be promising excipients in peroral delivery systems for peptide drugs.

[1]  S. Leeder,et al.  Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty. , 1986, The Journal of clinical endocrinology and metabolism.

[2]  Lisbeth Illum,et al.  Chitosan as a Novel Nasal Delivery System for Peptide Drugs , 1994, Pharmaceutical Research.

[3]  X. Zhou.  Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs , 1994 .

[4]  H. Junginger,et al.  Novel peroral dosage forms with protease inhibitory activities. I. Design of capsules with fast gel-forming and fast drug-releasing properties , 1996 .

[5]  H. Junginger,et al.  Novel peroral dosage forms with protease inhibitory activities. II. Design of fast dissolving poly(acrylate) and controlled drug-releasing capsule formulations with trypsin inhibiting properties , 1996 .

[6]  Claus-Michael Lehr,et al.  In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers , 1992 .

[7]  Gerrit Borchard,et al.  Mucoadhesive Polymers in Peroral Peptide Drug Delivery. II. Carbomer and Polycarbophil Are Potent Inhibitors of the Intestinal Proteolytic Enzyme Trypsin , 1995, Pharmaceutical Research.

[8]  S. Lundin,et al.  Biological effect and plasma concentrations of DDAVP after intranasal and peroral administration to humans. , 1986, General pharmacology.

[9]  Gerrit Borchard,et al.  The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro , 1996 .

[10]  P. Molinoff,et al.  Basic Neurochemistry: Molecular, Cellular and Medical Aspects , 1989 .

[11]  C. Larsen,et al.  Influence of experimental rhinitis on the gonadotropin response to intranasal administration of buserelin , 2004, European Journal of Clinical Pharmacology.

[12]  H. Junginger,et al.  In Vivo Buccal Delivery of the Peptide Drug Buserelin with Glycodeoxycholate as an Absorption Enhancer in Pigs , 1996, Pharmaceutical Research.